New Product Launch: Breckenridge Distillery has introduced a new beverage called Mountain Shot, which is infused with maitake mushrooms and available in whiskey-based and malt-based varieties.
Unique Flavor Profile: Mountain Shot combines rich chocolate and invigorating mint flavors, creating a distinct mouthfeel and experience for consumers, designed for enjoyment in various settings like mountainsides or bars.
Availability: The product is currently available in select U.S. markets in multiple formats, including 750-milliliter bottles, 1-liter bottles, and portable 100-milliliter pouches.
Company Background: Breckenridge Distillery, known for its award-winning spirits, aims to challenge conventions while celebrating craftsmanship, and is a subsidiary of Tilray Brands, Inc.
TLRY
$13.94+Infinity%1D
Analyst Views on TLRY
Wall Street analysts forecast TLRY stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for TLRY is 4.45 USD with a low forecast of 0.85 USD and a high forecast of 10.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
3 Analyst Rating
Wall Street analysts forecast TLRY stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for TLRY is 4.45 USD with a low forecast of 0.85 USD and a high forecast of 10.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
2 Buy
0 Hold
1 Sell
Moderate Buy
Current: 10.930
Low
0.85
Averages
4.45
High
10.00
Current: 10.930
Low
0.85
Averages
4.45
High
10.00
ATB Capital
Underperform -> Sector Perform
upgrade
$8.50
2025-12-10
Reason
ATB Capital
Price Target
$8.50
2025-12-10
upgrade
Underperform -> Sector Perform
Reason
ATB Capital upgraded Tilray to Sector Perform from Underperform with an $8.50 price target.
Jefferies
Kaumil Gajrawala
Buy
maintain
$2
2025-08-25
Reason
Jefferies
Kaumil Gajrawala
Price Target
$2
2025-08-25
maintain
Buy
Reason
Jefferies analyst Kaumil Gajrawala raised the firm's price target on Tilray to $2 from $1.50 and keeps a Buy rating on the shares. President Trump's recently expressed interest in rescheduling marijuana from Schedule I to Schedule III opens the door to broader access in the U.S. in a meaningful shift in federal stance that the analyst calls "not legalization, but progress." Tilray's has the brand strength, scale, and balance sheet to capture the opportunity in cannabis, the analyst contends.
Alliance Global Partners
Neutral
downgrade
$1
2025-07-22
Reason
Alliance Global Partners
Price Target
$1
2025-07-22
downgrade
Neutral
Reason
Alliance Global Partners lowered the firm's price target on Tilray to 75c from $1 and keeps a Neutral rating on the shares. The firm reduced estimates citing expected softness in the company's alcohol and international cannabis segments.
Piper Sandler
Michael Lavery
Hold
Maintains
$2 → $1
2025-04-09
Reason
Piper Sandler
Michael Lavery
Price Target
$2 → $1
2025-04-09
Maintains
Hold
Reason
Piper Sandler analyst Michael Lavery lowered the firm's price target on Tilray to $1 from $2 on diminished U.S. regulatory expectations, while keeping a Neutral rating on the shares. The firm notes Tilray reported $185.8M Q3 revenue, well below its $194.4M estimate.
About TLRY
Tilray Brands, Inc. is a global lifestyle and consumer packaged goods company. The Company operates through four segments: Cannabis operations, Distribution business, Beverage alcohol business and Wellness business. The Cannabis operations, which encompasses the production, distribution, sale, co-manufacturing and advisory services of both medical and adult-use cannabis. The Beverage alcohol operations, which encompasses the production, marketing and sale of beverage alcohol products. The Distribution operations, which encompasses the purchase and resale of pharmaceuticals products to customers. The Wellness products, which encompasses hemp foods and cannabidiol (CBD) products. The Company offers a portfolio of adult-use brands and products and expands its portfolio to include new cannabis products and formats. Its brands include Good Supply, RIFF, Broken Coast, Solei, Canaca, HEXO, Redecan, Original Stash, Hop Valley, Revolver, Bake Sale, XMG, Mollo, and others.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
